Q-omics provides the consensus-scored FAM96AP2 profile across patient tissues and cancer cell-line models. FAM96AP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM96AP2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FAM96AP2 RNA expression shows 17,174 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, HNSC, and THYM as cancer lineages where FAM96AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM96AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM96AP2 survival associations across molecular data types. FAM96AP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM96AP2 RNA expression–survival associations across cancer types. High FAM96AP2 expression shows unfavorable associations in KICH, THCA, STAD and CHOL, but favorable associations in LUSC and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FAM96AP2 RNA expression.
This table summarizes FAM96AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM96AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM96AP2 shows lower tumor expression in BRCA and higher tumor expression in HNSC, COAD, BLCA, LIHC and UCEC. The HNSC box plot shows higher FAM96AP2 RNA expression in tumor versus normal tissue (log2 FC = +1.434, t-test p < 0.001).
This table shows molecular features associated with FAM96AP2 in patient tissues and cancer cell lines. In patient samples, FAM96AP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
